Abstract 99P
Background
Immune checkpoint inhibitors (CPI) induced diarrhoea and colitis (ir-colitis) are common immune-related adverse events. Ir-colitis management guidelines are based on expert consensus. This retrospective study presents real-world data on melanoma patients with ir-colitis requiring medical intervention. The objective was to describe treatment patterns, hypothesising that glucocorticoid (GC) use exceeds guidelines and that biologic treatment (BIOx) initiation is often delayed.
Methods
Melanoma patients treated with CPI (anti-PD-1 and/or anti-CTLA4) in Southern Denmark (2013–2023) were identified from the Danish metastatic melanoma database. A validated AI language model was employed for identification of ir-colitis patients. Patient and treatment characteristics were analysed based on CPI regimen, CTCAE grade, sex, age, GC use, BIOx, and GC tapering failure.
Results
In 85 included patients (120 expected in the final cohort), predominantly female (n=47), the median (Mdn) age was 69 years (SD = 13.5), with 52% experiencing grade IV ir-colitis. Anti-CTLA4 regimens were the most common triggers, with 39% receiving monotherapy and 29% combination therapy. Forty-three patients achieved remission on GC alone, with Mdn prednisolone (PRED) dose of 1025 mg (IQR 600-1638). Among BIOx patients (n=38), the Mdn PRED dose was 2991 mg (IQR 1965-4403), with a Mdn interval of 17 days from GC initiation to BIOx. Infliximab was used in all BIOx patients; 11 required a second dose, and three needed a third. Mdn duration from GC initiation to complete tapering was 35 days (IQR 22-43) without BIOx and 65 days (IQR 49-93) with BIOx. Mdn duration from BIOx initiation to complete tapering was 45 days (IQR 29-67). Forty-two patients experienced failure during tapering, with Mdn GC usage of 2650 mg (IQR 1543-4403); among BIOx patients (n=24), Mdn GC usage was 3354 mg (IQR 2176-5027). In addition, peak GC dose and ir-colitis’s impact on survival compared with matched controls will be presented.
Conclusions
BIOx was required in 45% of cases, highlighting the need for optimised ir-colitis management by addressing excessive GC use and delayed initiation of BIOx. Further prospective studies are warranted, awaiting results from ongoing randomized clinical trials (e.g. NCT05947669).
Editorial acknowledgement
AI-assisted technology (ChatGPT-4) was used to improve the readability of the abstract at a final stage of abstract editing. After using these services, the authors reviewed and edited the content as needed and take full responsibility for the content of the abstract.
Legal entity responsible for the study
Department of Oncology, Odense University Hospital.
Funding
The research salary of SK(main author) were granted as part of his PhD. Grants were obtained by the Odense University Hospitals PhD fund and PhD fund of the Region of Southern Denmark. The Danish metastatic melanoma database is supported by Bristol Myers Squibb, Roche, Novartis, MSD, and Pierre Fabre. The funding bodies did not have any other role in the study.
Disclosure
C.H. Ruhlmann: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Helsinn Healthcare, MSD, Pharmanovia; Financial Interests, Personal, Other, Consultant: Astellas Pharma; Financial Interests, Institutional, Coordinating PI, Funding for a clinical trial; Helsinn Healthcare, Novo Nordisk Foundation. All other authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract